To The Moon

$Novo-Nordisk A/S(NVO)$

As I analyzed stocks trading at 52-week lows heading into 2025, I was surprised to find Novo Nordisk (NVO) on the list. NVO has been an incredible company and remains strong, yet it's down 20% for the month and 40% over the past six months. Despite this, it's still up over 200% over the last five years. Seeing it trading at such a low level left me curious to understand the reasons behind this significant decline. Is NVO presenting a generational buying opportunity, or could it be a value trap? I decided to dig deeper, and I’ll share my findings with you in this articles. We’ll explore why this stock appears to be significantly undervalued and why this may present a compelling buying opportunity, largely driven by what we believe is a market overreaction.

Before we proceed, I should clarify that I’m not an expert in the pharmaceutical industry. My only prior analysis of pharmaceutical stocks was on Pfizer, which has seen limited performance—flat or slightly down by 3-4%. Despite its reliable dividend and solid fundamentals, I generally avoid this sector. That said, here’s my sober analysis of NVO based on my research.

Key Reasons Behind the Decline

The main reason for NVO's recent drop seems to be related to their next-generation obesity drug, codenamed Cagrilintide, which follows their successful GLP-1 injection drug, Wegovy. While the company expected weight loss results of around 25%, the clinical trial data showed an average weight loss of 22.7% after 68 weeks. Although 40.4% of patients achieved the 25% target, the slight miss triggered a market overreaction, sending the stock tumbling.

This outcome highlights what happens when a stock is priced to perfection—NVO was trading at about 40 times earnings. Even a small miss can lead to a significant correction, as we've seen here.

The stock’s most notable drop—20% in a single session—was primarily triggered by disappointing trial results for their obesity drug, Wegovy. The trial showed an average weight reduction of 22.7%, falling short of analysts’ expectations of around 25%. While the difference was marginal, the market reacted strongly, causing a significant sell-off.

Over the past month, the stock is down approximately 21%, contributing to a total year-to-date decline of 37%. However, on a broader scale, the stock remains a strong performer, up 37% over the past decade, even with the recent downturn.

Challenges And Risk

Another challenge is the influx of competition—over 60 new weight-loss drugs are expected to enter the market by 2029. Companies like Pfizer and Bristol Myers Squibb are developing alternatives, while telehealth companies like Him & Hers are offering cheaper compounded versions of GLP-1 drugs.

Despite these concerns, NVO is proactive. Their recent $65 billion acquisition of Catalent, which analysts expect to generate $100 billion in future annual sales, demonstrates their strategic foresight. With high net income margins (~35-36%), NVO's management is positioning the company well for the long term.

Novo Nordisk’s stock price has experienced a significant drop from its highs in early 2024, prompting many investors to question whether the stock is currently undervalued. In this video, I'll address that question by conducting a discounted cash flow (DCF) valuation analysis of Novo Nordisk's stock. I'll also detail where I'm sourcing all the numbers and inputs for the model, ensuring transparency about their accuracy, potential underestimation, or overestimation.

Recent Price Trends and Inputs

Looking at Novo Nordisk’s stock price over the last three years, it saw substantial gains during 2022 and 2023, peaking in mid-2024, but has since declined. To estimate the intrinsic value of the stock, I utilized the following inputs:

• Market Cap: $382 billion

• Cash and Equivalents: $8.5 billion

• Long-Term Debt: $8.5 billion

• Average Diluted Shares Outstanding: 4.46 billion

Additionally, I referenced Wall Street analysts’ free cash flow estimates:

• $9.6 billion (2024)

• $13 billion (2025)

• $17 billion (2026)

• $19.5 billion (2027)

• $22 billion (2028)

This impressive growth is largely driven by Novo Nordisk's breakthroughs in obesity and diabetes treatments over the last three years.

Risk Profile and Beta

Novo Nordisk’s beta is 0.17, indicating significantly lower volatility compared to the overall market. Healthcare companies like Novo Nordisk are less correlated to economic cycles since demand for treatments isn’t directly tied to income levels or job growth. While some economic influence exists (e.g., access to healthcare for the unemployed), it's minimal compared to industries like retail.

Fundamental Strengths

Despite the recent volatility, Novo Nordisk continues to display strong fundamentals:

Revenue Streams: The majority of revenue comes from diabetes care, with the GLP-1 drug class being the largest contributor at $35 billion in the latest quarter.

Earnings Growth: Double-digit growth continues across key metrics, with Q3 2024 net profit up 177% year-on-year. Revenue for the first nine months of 2024 increased by 23%, with gross margin improving to 84.6%.

Dividends: A 1.7% dividend yield, above its five-year average, solidifies its status as a dividend growth company, increasing payouts by 52% in the past year.

Valuation Indicators

Several models suggest significant undervaluation:

• PE Ratio: The forward PE of 22.6 is below both the S&P 500 average and Novo Nordisk’s five-year average of 30.4.

• Dividend Yield Theory: The current yield exceeds its historical average, indicating undervaluation.

• DCF Model: Strong free cash flow growth, consistent share buybacks, and a high ROIC (67%) further support the thesis of undervaluation.

Fundamental Analysis

Income Statement Highlights

Novo Nordisk's net income has grown from $4.3 billion in 2014 to $12.4 billion, a near threefold increase, closely mirroring revenue growth. By December 2024, net income is expected to grow an additional 10%. This robust growth demonstrates strong operational efficiency and profitability.

Balance Sheet Strength

Novo Nordisk boasts a solid balance sheet:

• Cash Reserves: Increased fivefold over the past decade, now at $11.2 billion.

• Debt Management: Total debt has risen to $8.6 billion, but cash reserves exceed debt, enabling immediate repayment if needed.

• Cash Generation: Cash from operations has grown from $5 billion in 2014 to $18 billion, an impressive threefold increase.

Novo Nordisk boasts exceptional financial metrics:

• Free Cash Flow: Consistent growth over the past decade, tripling in value.

• Margins: Operating and free cash flow margins remain robust, signaling efficiency.

• Debt Management: The company has virtually no net debt, with the ability to cover all obligations immediately using cash on hand.

Institutional Activity

Institutional investors currently hold 11.5% of Novo Nordisk, with $4.2 billion in purchases and $3 billion in sales over the past year, reflecting a generally bullish outlook. However, in Q3, there was slightly more selling than buying, albeit by a marginal amount in the hundreds of thousands.

Valuation Overview

Novo Nordisk trades at a premium, with a forward P/E ratio 37% above the sector median. While this earns a D- for valuation, the premium may be justified given its growth potential and profitability metrics, which significantly outperform sector averages.

• Growth (A-): Revenue growth of 26% year-over-year, far exceeding the sector average of 7.7%.

• Profitability (A+): Operating margins at 35% versus the sector's -42%, with cash from operations reaching $18 billion while the sector median burns through $15 million.

Performance and Intrinsic Valuation

Past Performance: Novo Nordisk has outperformed over the last 5 and 10 years but underperformed in the past year.

DCF Valuation: Based on free cash flow growth of 11-14%, the intrinsic value is estimated at $117 per share, suggesting a 34% upside. Adjusting for different discount rates, the value ranges from $102 to $134, offering upside potential of 17-54%.

Valuation

From a valuation perspective, the forward P/E ratio has dropped from 40-50x earnings to a more reasonable 22-23x earnings. Analysts predict 22% EPS growth for 2025, followed by a gradual decline to ~13% growth in the following years. Using these estimates, I project earnings per share to reach $6.33 by 2029.

Assuming a fair P/E multiple of 23x earnings, this would imply a price of $145 per share by 2029. With the current price at $86, that represents a 69% upside over five years. While this isn’t unattractive, it’s not particularly exciting given the uncertainties surrounding the weight-loss market and potential regulatory changes.

For me, a more attractive entry point would be $72 per share, which would offer a better margin of safety and room for upside. While I believe NVO is a solid company, I see more compelling opportunities elsewhere in the market at this time.

The DCF analysis uses Wall Street's free cash flow estimates for the first several years, projecting 22% growth until 2034. Beyond that, I forecast:

• 11% annual growth (2030–2034)

• 5% long-term growth from 2035 onward

The present value of cash flows (2024–2034) is $181 billion, and the terminal value (2035 onward) is $1.8 trillion, resulting in a total operational value of approximately $2 trillion.

Conclusion

While Novo Nordisk’s metrics are compelling, investors should consider the heavy reliance on GLP-1 drugs for revenue. Wall Street remains optimistic, with a price target of $148, indicating a 70% upside over the next year.

Novo Nordisk demonstrates robust cash flow potential fueled by its success in treating obesity and diabetes. Based on my analysis, the stock appears undervalued across various scenarios. For those interested, my new book outlines the framework I use to evaluate stocks, offering further insights into identifying undervalued opportunities like Novo Nordisk.

Novo Nordisk’s recent sell-off appears unwarranted, given the company’s strong fundamentals, double-digit revenue growth, and robust financial health. The current price levels present a compelling opportunity for investors to capitalize on market overreaction, especially with multiple valuation models indicating that the stock is undervalued.

What’s your take on Novo Nordisk? Have you added it to your portfolio after the recent drop below $87, or are you cautious due to potential risks? Share your thoughts below!

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub